Osteoarthritis represents a significant unmet medical condition with disease-modifying treatments currently unavailable. Though oral medications (NSAIDs, COX-2 inhibitors, etc.) and intraarticular injections (corticosteroids and hyaluronic acids) are noninvasive, these treatment options are only capable of reducing the symptomatic pain associated with osteoarthritis. Surgical interventions (arthroscopic debridement, osteotomy, microfracture, joint replacement, etc.) are invasive, expensive, and are unable to effectively address the underlying pathology of the disease. In contrast, TG-C has the potential to become the first noninvasive therapy to effectively treat osteoarthritis by reversing cartilage damage, relieving arthritic symptoms and improving knee function.
TissueGene's allogeneic cells (i.e. donor cells) can be mass-cultured and mass-packaged; and consequently, the products can be delivered in a ready-to-inject, off-the-shelf form to any patient immediately upon diagnosis of the damaged tissue. In contrast to competing autologous cell (i.e. a patient’s own cells) therapies, no harvesting of cells is required, nor any culturing of patient cells. The elimination of invasive surgical procedures and the added simplicity of administering the product with a hypodermic needle allows for more patients to be treated in less time and with less postoperative care. Additionally, the time and money saved by eliminating the need to genetically modify and cultivate each and every patient’s harvested cells is tremendous, making allogeneic treatment very attractive from a commercial standpoint.